Stock Research for VTWO

VTWO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

VTWO Stock Chart & Research Data

The VTWO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VTWO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


VTWO Due diligence Resources & Stock Charts

The VTWO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View VTWO Detailed Price Forecast - CNN Money CNN View VTWO Detailed Summary - Google Finance
Yahoo View VTWO Detailed Summary - Yahoo! Finance Zacks View VTWO Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View VTWO Trends & Analysis - Trade-Ideas Barrons View VTWO Major Holders - Barrons
NASDAQ View VTWO Call Transcripts - NASDAQ Seeking View VTWO Breaking News & Analysis - Seeking Alpha
Spotlight View VTWO Annual Report - CompanySpotlight.com OTC Report View VTWO OTC Short Report - OTCShortReport.com
TradeKing View VTWO Fundamentals - TradeKing Charts View VTWO SEC Filings - Bar Chart
WSJ View Historical Prices for VTWO - The WSJ Morningstar View Performance/Total Return for VTWO - Morningstar
MarketWatch View the Analyst Estimates for VTWO - MarketWatch CNBC View the Earnings History for VTWO - CNBC
StockMarketWatch View the VTWO Earnings - StockMarketWatch MacroAxis View VTWO Buy or Sell Recommendations - MacroAxis
Bullish View the VTWO Bullish Patterns - American Bulls Short Pains View VTWO Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View VTWO Stock Mentions - StockTwits PennyStocks View VTWO Stock Mentions - PennyStockTweets
Twitter View VTWO Stock Mentions - Twitter Invest Hub View VTWO Investment Forum News - Investor Hub
Yahoo View VTWO Stock Mentions - Yahoo! Message Board Seeking Alpha View VTWO Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for VTWO - SECform4.com Insider Cow View Insider Transactions for VTWO - Insider Cow
CNBC View VTWO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for VTWO - OTC Markets
Yahoo View Insider Transactions for VTWO - Yahoo! Finance NASDAQ View Institutional Holdings for VTWO - NASDAQ


Stock Charts

FinViz View VTWO Stock Insight & Charts - FinViz.com StockCharts View VTWO Investment Charts - StockCharts.com
BarChart View VTWO Stock Overview & Charts - BarChart Trading View View VTWO User Generated Charts - Trading View


Latest Financial News for VTWO

The Role of Securities Lending in ETF Returns
Posted on Wednesday April 18, 2018

ETFs produce significant revenue by lending out securities, but there are risks associated with the practice.


Where Atara Biotherapeutics Stands This January: Analyst Ratings
Posted on Wednesday January 31, 2018

Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.


Does Accelerate Diagnostics’ Financial Performance Bode Well?
Posted on Monday January 15, 2018

How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.


Decoding the Advisory Board’s Net Profit Margins in 2017
Posted on Thursday July 13, 2017

In 1Q17, the Advisory Board (ABCO) reported adjusted EBITDA of ~$45 million, which was higher than its guidance of $37 million–$42 million.


Enter a stock symbol to view the stock details.